NCT05518253

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Recruiting now Phase 1 Last updated 31 May 2025

What this trial tests

Phase 1 trial testing CD70 CAR-T cells in Metastatic Tumor in 30 participants. Currently enrolling.

Timeline

30 May 2022

Primary endpoint
30 May 2026

30 May 2027

Quick facts

Lead sponsor	Weijia Fang, MD
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	30 May 2022
Primary completion	30 May 2026
Estimated completion	30 May 2027
Sites	1 location across China

Drugs / interventions tested

• CD70 CAR-T cells
• CD70 CAR-T cells

Conditions studied

• Metastatic Tumor — all drugs for Metastatic Tumor →
• Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
• Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →
• Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Weijia Fang, MD — full company profile →

Who can join

18 and older, any sex, with Metastatic Tumor or Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment.
   Yan T, Zhu L, Chen J. · · 2023 · cited 132× · PMID 36707873 · DOI 10.1186/s40164-023-00373-7
2. Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
   Dagar G, Gupta A, Masoodi T, Nisar S, et al · · 2023 · cited 130× · PMID 37420216 · DOI 10.1186/s12967-023-04292-3
3. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
   Shin MH, Oh E, Kim Y, Nam DH, et al · · 2023 · cited 49× · PMID 37371075 · DOI 10.3390/cells12121606
4. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
   Meng L, Collier KA, Wang P, Li Z, et al · · 2023 · cited 48× · PMID 38201238 · DOI 10.3390/cells13010034
5. Human papillomavirus associated cervical lesion: pathogenesis and therapeutic interventions.
   Ye J, Zheng L, He Y, Qi X. · · 2023 · cited 27× · PMID 37719443 · DOI 10.1002/mco2.368
6. CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?
   Cutri-French C, Nasioudis D, George E, Tanyi JL. · · 2024 · cited 23× · PMID 38667465 · DOI 10.3390/diagnostics14080819
7. Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics.
   Cheng J, Zhao Y, Hu H, Tang L, et al · · 2023 · cited 18× · PMID 37382633 · DOI 10.1007/s00262-023-03475-7
8. Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.
   Qin Y, Xu G. · · 2022 · cited 18× · PMID 36569859 · DOI 10.3389/fimmu.2022.1053120